Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood.

Bhattoa, Harjit P.; Cavalier, Etienne; Eastell, Richard; Heijboer, Annemieke C.; Jørgensen, Niklas R.; Makris, Konstantinos; Ulmer, Candice Z.; Kanis, John A.; Cooper, Cyrus; Silverman, Stuart L.; Vasikaran, Samuel D.

doi:10.1016/j.cca.2020.12.023

Article (Scientific journals)

Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood.

Bhattoa, Harjit P.; Cavalier, Etienne; Eastell, Richard et al.

2020 • In Clinica Chimica Acta, 515, p. 16-20

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/257476

DOI
10.1016/j.cca.2020.12.023

PubMed
33382995

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

1-s2.0-S000989812030591X-main (1).pdf

Publisher postprint (1.1 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Bone formation; Bone resorption; Bone turnover markers; C-terminal telopeptide of type I collagen; Harmonization; PINP; Procollagen type I N-propeptide; Standardization; β-CTX

Abstract :

[en] Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood have been designated as reference bone turnover markers in osteoporosis by the International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). The IFCC Committee on Bone Metabolism (C-BM) has examined current commercial assays and performed a multicentre study to examine the agreement between assays for PINP and β-CTX in serum and plasma. The results of these studies will inform our work towards the harmonization of PINP assays and the standardization of β-CTX assays in blood, with the development of common calibrators and reference measurement procedures in collaboration with the reagent manufacturing industry. Successful achievement of these goals will help develop universally acceptable practice guidelines for the management of osteoporosis with the inclusion of common reference intervals and treatment targets for PINP and β-CTX.

Disciplines :

Laboratory medicine & medical technology

Author, co-author :

Bhattoa, Harjit P.

Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

Eastell, Richard

Heijboer, Annemieke C.

Jørgensen, Niklas R.

Makris, Konstantinos

Ulmer, Candice Z.

Kanis, John A.

Cooper, Cyrus

Silverman, Stuart L.

Vasikaran, Samuel D.

Language :

English

Title :

Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood.

Publication date :

December 2020

Journal title :

Clinica Chimica Acta

ISSN :

0009-8981

eISSN :

1873-3492

Publisher :

Elsevier, Netherlands

Volume :

515

Pages :

16-20

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 26 February 2021

Statistics

Number of views

47 (1 by ULiège)

Number of downloads

4 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Consensus Development Conference, Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94 (1993), 646–650.
Cheng, S.Y., Levy, A.R., Lefaivre, K.A., Guy, P., Kuramoto, L., Sobolev, B., Geographic trends in incidence of hip fractures: a comprehensive literature review. Osteoporos. Int. 22 (2011), 2575–2586.
Kanis, J.A., McCloskey, E.V., Johansson, H., Oden, A., Melton, L.J., Khaltaev, N., A reference standard for the description of osteoporosis. Bone 42 (2008), 467–475.
McCloskey, E.V., Johansson, H., Oden, A., Kanis, J.A., From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr. Osteoporos. Rep. 7 (2009), 77–83.
Khosla, S., Hofbauer, L.C., Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 5 (2017), 898–907.
Eastell, R., Pigott, T., Gossiel, F., Naylor, K.E., Walsh, J.S., Peel, N.F., Diagnosis of endocrine disease: Bone turnover markers: are they clinically useful?. Eur. J. Endocrinol. 178 (2018), R19–R31.
Diez-Perez, A., Naylor, K., Abrahamsen, B., Agnusdei, D., Brandi, M.L., Cooper, C., Dennion, E., Eriksen, E.F., Gold, D.T., Guañabens, N., Hadji, P., Hiligsmann, M., Oorne, R., Josse, R., Kanis, J.A., Obermayer-Pietsch, B., Prieto-Alhambra, D., Reginster, J.-Y., Rizzoli, R., Silverman, S., Zillikens, M.C., Eastell, R., International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos. Int. 28 (2017), 767–774.
Lorentzon, M., Branco, J., Brandi, M.L., Bruyère, O., Chapurlat, R., Cooper, C., Cortet, B., Diez-Perez, A., Ferrari, S., Gasparik, A., Herrmann, M., Jorgensen, N.R., Kanis, J., Kaufman, J.M., Laslop, A., Locquet, M., Matijevic, R., McCloskey, E., Minisola, S., Pikner, R., Reginster, J.Y., Rizzoli, R., Szulc, P., Vlaskovska, M., Cavalier, E., Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv. Ther. 36 (2019), 2811–2824.
Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A.J., Garnero, P., Griesmacher, A., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22 (2011), 391–420.
Robey, P.G., Fisher, L.W., Young, M.F., Termine, J.D., The biochemistry of bone. Riggs, B.L., Melton, L.J., (eds.) Osteoporosis: Etiology, Diagnosis and Management, 1988, Raven Press, New York, 95–109.
Calvo, M.S., Eyre, D.R., Gundberg, C.M., Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17 (1996), 333–338.
Eyre, D.R., Cross-linking in collagen and elastin. Annu. Rev. Biochem. 53 (1984), 717–748.
Teisner, B., Rasmussen, H.B., Højrup, P., Yde-Andersen, E., Skjødt, K., Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the alpha 1 chain of human procollagen type I. APMIS 100 (1992), 1106–1114.
Fay, T.N., Jacobs, I., Teisner, B., Poulsen, O., Chapman, M.G., Stabile, I., et al. Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues. Eur. J. Obstet. Gynecol. Reprod. Biol. 29 (1988), 73–85.
Orum, O., Hansen, M., Jensen, C.H., et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 19 (1996), 157–163.
Price, K.M., Silman, R., Armstrong, P., Grudzinskas, J.G., Development of a radioimmunoassay for fetal antigen 2. Clin. Chim. Acta 224 (1994), 95–102.
Melkko, J., Kauppila, S., Niemi, S., Risteli, L., Haukipuro, K., Jukkola, A., et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin. Chem. 42 (1996), 947–954.
Jensen, C.H., Hansen, M., Brandt, J., Rasmussen, H.B., Jensen, P.B., Teisner, B., Quantification of the N-terminal propeptide of human procollagen type I (PINP): comparison of ELISA and RIA with respect to different molecular forms. Clin. Chim. Acta 269 (1998), 31–41.
Brandt, J., Krogh, T.N., Jensen, C.H., Frederiksen, J.K., Teisner, B., Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin. Chem. 45 (1999), 47–53.
Tahtela, R., Turpeinen, M., Sorva, R., Karonen, S.L., The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin. Biochem. 30 (1997), 35–40.
Koivula, M.K., Richardson, J., Leino, A., Valleala, H., Griffiths, K., Barnes, A., et al. Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clin. Biochem. 43 (2010), 1453–1457.
Garnero, P., Vergnaud, P., Hoyle, N., Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin. Chem. 54 (2008), 188–196.
Bonde, M., Qvist, P., Fledelius, C., Riis, B.J., Christiansen, C., Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin. Chem. 40 (1994), 2022–2225.
Rosenquist, C., Fledelius, C., Christgau, S., Pedersen, B.J., Bonde, M., Qvist, P., et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 44 (1998), 2281–2289.
Szulc, P., Naylor, K., Hoyle, N.R., Eastell, R., Leary, E.T., National Bone Health Alliance Bone Turnover Marker Project. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos. Int. 28 (2017), 2541–2556.
Bonde, M., Garnero, P., Fledelius, C., Qvist, P., Delmas, P.D., Christiansen, C., Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J. Bone Miner. Res. 12 (1997), 1028–1034.
Crofton, P.M., Evans, N., Taylor, M.R., Holland, C.V., Serum CrossLaps: pediatric reference intervals from birth to 19 years of age. Clin. Chem. 48 (2002), 671–673.
Rogers, A., Glover, S.J., Eastell, R., A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 45 (2009), 1044–1052.
Garnero, P., Borel, O., Delmas, P.D., Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin. Chem. 47 (2001), 694–702.
Seres, Z., Dixon, C., Middlemist, S., Wynn, C., Laurie, D., Fox, C., Barnes, A., Garrity, M., A new β-crosslaps® (CTX-I) assay on the IDS-ISYS automated analyser. Bone, 47, 2010, S143.
Cavalier, E., Eastell, R., Rye Jørgensen, N., Makris, K., Tournis, S., Vasikaran, S., et al. IFCC-IOF Joint Committee for Bone Metabolism (C-BM). A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. Clin. Chem. Lab. Med. 57 (2019), 1546–1555.
Jørgensen, N.R., Møllehave, L.T., Hansen, Y.B.L., Quardon, N., Lylloff, L., Linneberg, A., Comparison of two automated assays of BTM (CTX and PINP) and reference intervals in a Danish population. Osteoporos. Int. 28 (2017), 2103–2113.
Koivula, M.K., Ruotsalainen, V., Björkman, M., Nurmenniemi, S., Ikäheimo, R., Savolainen, et al. Difference between total and intact assays for N-terminalpropeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann. Clin. Biochem. 47:47 (2010), 67–71.
Morovat, A., Catchpole, A., Meurisse, A., Carlisi, A., Bekaert, A.C., Rousselle, O., Paddon, M., James, T., Cavalier, E., IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children. Clin. Chem. Lab. Med. 51 (2013), 2009–2018.
Cavalier, E., Lukas, P., Carlisi, A., Gadisseur, R., Delanaye, P., Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin. Chim. Acta 425 (2013), 117–118.
Wheater, G., Goodrum, C., Tuck, S.P., Datta, H.K., van Laar, J.M., Method-specific differences in beta-isomerised carboxy-terminal cross-linking telopeptide of type I collagen and procollagen type I amino-terminal propeptide using two fully automated immunoassays. Clin. Chem. Lab. Med. 52 (2014), e135–e138.
Vasikaran, S.D., Bhattoa, H.P., Eastell, R., Heijboer, A.C., Jørgensen, N.R., Makris, K., Ulmer, C., Kanis, J.A., Cooper, C., Silverman, S., Cavalier, E., Harmonization of commercial assays for PINP; the way forward. Osteoporos. Int. 31 (2020), 409–412.
Chubb, S.A., Mandelt, C.D., Vasikaran, S.D., Comparison of results from commercial assays for plasma CTX: The need for harmonization. Clin. Biochem. 48 (2015), 519–524.